1 / 13

c-KIT and Gastrointestinal Stromal Tumors (GISTs)

c-KIT and Gastrointestinal Stromal Tumors (GISTs). Stefanie Chua 30 March 2004. What is KIT?. Transmembrane type III tyrosine kinase receptor c-KIT is the cellular homologue of v-KIT Maps to chromosome 4 (4q11-12). Where is KIT found?. Hematopoietic stem cells Mast cells

tomas
Download Presentation

c-KIT and Gastrointestinal Stromal Tumors (GISTs)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. c-KIT and Gastrointestinal Stromal Tumors (GISTs) Stefanie Chua 30 March 2004

  2. What is KIT? • Transmembrane type III tyrosine kinase receptor • c-KIT is the cellular homologue of v-KIT • Maps to chromosome 4 (4q11-12)

  3. Where is KIT found? • Hematopoietic stem cells • Mast cells • Melanocytic cells • Germ cells • Gametophytes • **Interstitial cells of Cajal (ICC)

  4. Structure of KIT • Extracellular domain • Transmembrane domain • Intracellular domain • Mutations are typically found in the kinase domain

  5. Ligand: SCF • Ligand for KIT: stem cell factor (SCF) or Steel • It is found on… • bone marrow stroma cells • Fibroblasts • Keratinocytes • intestinal epithelial cells • Sertoli’s cells • granulosa cells

  6. KIT Activation

  7. Knockout Mice • Homozygous recessive mouse: dies within days because of macrocytic anemia • Heterozygous mouse: defect in pigmentation with white spotting phenotype, piebaldism.

  8. KIT mutation • Like most RTKs, KIT kinase has multiple levels of control, therefore, a number of phenotypic changes are observed because KIT is found in a number of different cells including stem and germ cells. • These types of mutations result in a loss of kinase function. • BUT… gain of function mutations are involved in the induction of tumors of ICCs to form GISTs

  9. KIT and SCF • Heterozygous for a loss of function mutation • Only have half of the normal amount of KIT gene product • Shortage of red blood cells • Shortage of pigment cells • Shortage of germ cells

  10. Gastrointestinal Stromal Tumors (GISTs) • GISTs develop from ICCs • GISTs and ICCs are double positive for KIT and CD34.

  11. GISTs in relation to KIT • 84 – 100% of GISTs express constitutively active KIT • KIT oncogenic activation occurs in the early stages of benign GIST formation • Not dependent on binding of KIT ligand • Have structural changes that favor receptor oligomerization and cross phosphorylation even in the absence of ligand • When mutation occurs in KIT, the tyrosine kinase activity of KIT is constitutively gained without the binding of SCF.

  12. Treatment: Gleevac • Chemotherapy and radiation are not conducive to the treatment GISTs • It was found that KIT oncoproteins have the same active enzymatic site as native KIT. Therefore, kinase inhibitors like STI-571 (Gleevac)bind well and are effective inhibitors of constitutively activated molecules.

  13. Works Cited Hirota S. Gastrointestinal stromal tumors: their origin and cause. [Review] International Journal of Clincal Oncology. 6(1): 1-5, 2001 Feb. Taylor ML. Metcalfe DD. Kit signal transduction [Review] Hematology – Oncology Clinics of North America. 14(3): 517-25, 2000 Jun. Heinrich MC. Rubin BP. Longle BJ. Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. [Review] Human Pathology. 33(5): 484 –95, 2002 May. Ashman LK. The biology of stem cell factor and its receptor C-kit. [Review] International Journal of Biochemistry and Cell Biology. 31(1999): 1037-1051, 1999 Feb. Longley BJ. Reguera MJ. Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. [Review] Leukemia Research. 25(2001): 571-576, 2001 Jan. Waskow C. Rodewald HR. Lymphocyte development in neonatal and adult c-Kit-deficient mice. [Review] Advances in Experimental Medicine and Biology. 512:1-10, 2002. Gilbert, Scott F. Developmental Biology, 7th ed. 2003: USA. Sinauer Associates, Inc.

More Related